Al Khaja K A Jassim, Sequeira R P
Department of Pharmacology and Therapeutics, College of Medicine and Medical Sciences, Arabian Gulf University, Kingdom of Bahrain.
Pharmacoepidemiol Drug Saf. 2006 Oct;15(10):741-8. doi: 10.1002/pds.1161.
To compare pattern of antihypertensive drug utilization in 1998 with 2000 following the: (a) publication of 1999 World Health Organization/International Society of Hypertension (WHO/ISH) guidelines for drug management of hypertension; and (b) introducing new antihypertensives to the essential drug list, in primary care, Bahrain.
Retrospective prescription-based survey carried out in seven out of 20 primary care health centers in Bahrain. A total of 9272 patients comprising 6543 with uncomplicated hypertension and 2729 with diabetic hypertension were studied.
Between 1998 and 2000, the prescription rate of beta-blockers and methyldopa significantly declined (p < 0.0001) while the rate of angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers (CCBs) increased (p < 0.0001) in uncomplicated hypertension. However, in diabetic hypertension there was a non-significant decline in utilization of beta-blockers, CCBs, methyldopa, and diuretics whereas a significant increase in prescribing of ACE inhibitors (p < 0.0001). Inclusion of Perindopril into the essential drug list resulted in an overall increase in utilization of ACE inhibitors: use of captopril and enalapril declined while lisinopril and perindopril increased. Substitution of immediate-release (IR) indapamide by sustained-release (SR) formulation did not change the overall utilization of diuretics; however, intra-class changes were evident with a significant decline in use of thiazide diuretics and concomitant increase in use of SR indapamide by 2000.
The antihypertensive prescribing pattern is influenced by WHO/ISH guidelines as well as by introduction of new antihypertensives to primary care essential drug list in primary care. The choice of a drug is also influenced by presence of co-morbidity with diabetes mellitus.
比较1998年和2000年巴林初级保健机构中抗高血压药物的使用模式,具体如下:(a) 1999年世界卫生组织/国际高血压学会(WHO/ISH)高血压药物管理指南发布之后;(b) 在初级保健机构的基本药物清单中引入新型抗高血压药物之后。
在巴林20家初级保健健康中心中的7家开展基于处方的回顾性调查。共研究了9272例患者,其中6543例为单纯性高血压患者,2729例为糖尿病性高血压患者。
1998年至2000年期间,单纯性高血压患者中β受体阻滞剂和甲基多巴的处方率显著下降(p < 0.0001),而血管紧张素转换酶(ACE)抑制剂和钙通道阻滞剂(CCB)的处方率上升(p < 0.0001)。然而,在糖尿病性高血压患者中,β受体阻滞剂、CCB、甲基多巴和利尿剂的使用量有非显著性下降,而ACE抑制剂的处方量显著增加(p < 0.0001)。培哚普利被列入基本药物清单导致ACE抑制剂的总体使用量增加:卡托普利和依那普利的使用量下降,而赖诺普利和培哚普利的使用量增加。速释型吲达帕胺被缓释型制剂取代并未改变利尿剂的总体使用情况;然而,到2000年,类内变化明显,噻嗪类利尿剂的使用量显著下降,同时缓释型吲达帕胺的使用量相应增加。
抗高血压药物的处方模式受WHO/ISH指南以及初级保健机构基本药物清单中新型抗高血压药物引入的影响。药物的选择还受糖尿病合并症的影响。